Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jul 2001

Haiman C A, Stampfer M J, Giovannucci E, Ma J, Decalo N E, Kantoff P W, Hunter D J

Abstract excerpt

The A2 allele of the CYP17 gene has been thought to be associated with increased functional activity of this steroidogenic enzyme. Consequently, the A2 allele has been examined as a biomarker of individual susceptibility to hormone-related diseases among men and women. We prospectively assessed the association between the A2 allele of CYP17 and prostate cancer risk among 590 cases and 782 controls in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Gonadal Steroid Hormones

Share to Odds Ratio

Share to Prostatic Neoplasms

Share to Risk Factors

Share to Steroid 17-alpha-Hydroxylase

Source

Identifiers

PMID: 11440959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.PMID 11440959Read ↗

A polymorphism in the CYP17 gene and risk of prostate cancer.Semantic proximity Read ↗

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).Semantic proximity Read ↗

Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.Semantic proximity Read ↗

The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.Semantic proximity Read ↗

A polymorphism in CYP17 and endometrial cancer risk.Semantic proximity Read ↗

Prostate cancer associated with CYP17 genotype.Semantic proximity Read ↗

A2 allele polymorphism of the CYP17 gene and prostate cancer risk in an iranian population.Semantic proximity Read ↗

The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.Semantic proximity Read ↗

Polymorphism in the Androgen Biosynthesis Gene (CYP17), a Risk for Prostate Cancer: A Meta-Analysis.Semantic proximity Read ↗

Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.Semantic proximity Read ↗

CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population.Semantic proximity Read ↗

Genetic polymorphism in sex hormone metabolism and prostate cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.